OABI
OmniAbDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that OmniAb’s 107 active partners, 407 active programs and growing set of later-stage partnered assets can gradually convert a low-revenue platform story into a milestone-and-royalty story, while OmniUltra and xPloration widen platform relevance and help sustain partner additions [#8-K-2026-03-04].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
2026 guidance still implies meaningful cash burn and a lower year-end cash balance.
Momentum
87
Value
41
Sentiment
4
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $2.40 · Bear $0.70
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $7.36
Why
Momentum87 · Δ7d -
Value41 · Δ7d +0.1
Sentiment4 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
87
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
4
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 86.8 / Value 41.1 / Sentiment 4.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$378.38M
Beta
0.15
Shares Out
143.96M
P/E (TTM) · Derived
-4.3
P/S (TTM)
12.63
P/FCF (TTM) · Derived
-8.04
Rev YoY
-46.3%
EPS YoY
+9.9%
Gross Margin
+27.7%
Op Margin
-327.5%
Net Debt
-$59.43M
Current Ratio
5.00
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology